Tesofensine is a novel triple monoamine reuptake inhibitor, which means it blocks the reuptake of three neurotransmitters: dopamine, norepinephrine, and serotonin. It was originally developed by NeuroSearch, a Danish pharmaceutical company, for the treatment of neurological disorders such as Alzheimer’s and Parkinson’s disease. However, during the trials, it was observed that overweight participants experienced significant weight loss. This led to a shift in the development of tesofensine towards obesity treatment.

**Use the code HLI to save 10%**